斜生褐孔菌多糖诱导人肝癌HepG-2细胞凋亡的研究

研究了斜生褐孔菌多糖对人类肝癌HepG-2细胞凋亡的诱导作用。采用噻唑蓝法(MTT法)观察了斜生褐孔菌多糖对HepG-2细胞生长的影响,用透射电镜观察了细胞形态,用DNA Ladder检测了细胞凋亡,用流式细胞仪检测了细胞凋亡率;同时采用逆转录-聚合酶链反应法(RT-PCR法)研究了不同浓度斜生褐孔菌多糖作用后HepG-2细胞中Bax和Bcl-2基因mRNA转录水平的变化。结果表明斜生褐孔菌多糖能抑制HepG-2细胞增殖,并呈时间剂量依赖关系;电镜观察、DNALadder和流式细胞仪检测均证实了斜生褐孔菌多糖能够诱导HepG-2细胞凋亡;经斜生褐孔菌多糖处理后,HepG-2细胞中Bax基因mRNA转录水平增强,而Bcl-2基因mRNA无明显变化。证明了斜生褐孔菌多糖具有抑制HepG-2细胞生长及诱导HepG-2细胞凋亡的作用,这可能与调节Bcl-2和Bax基因表达水平有关。     

结核分枝杆菌融合蛋白Ag85B-Hsp16.3、Ag85B-ESAT6 和分泌蛋白 Hsp16.3 体外对人肝癌细胞HepG-2 的作用*

目的:探讨结核分枝杆菌融合蛋白Ag85B-Hsp16.3、Ag85B-ESAT6及分泌蛋白Hsp16.3对人肝癌细胞HepG-2的作用。方法:将已构建的含3种目的基因的表达载体pProEXHTa-Ag85B-Hsp16.3、pProEXHTa-Ag85B-ESAT6和pProEXHTb-Hsp16.3,分别转入宿主菌E.coliDH5α中,诱导表达后分别获得Ag85B-Hsp16.3、Ag85B-ESAT6和Hsp16.3三种蛋白,采用Ni2+亲和层析柱进行纯化,并用透析方法进行目的蛋白的复性。复性的蛋白按照不同浓度和作用时间分别与肝癌细胞HepG-2反应,用MTT法检测细胞生长情况。结果:三种蛋白被成功纯化并复性。MTT数据统计分析显示,终浓度10μg/ml的三种蛋白对HepG-2细胞生长没有明显作用,当三种蛋白的终浓度分别为20、40、80μg/ml时均能够抑制HepG-2细胞的生长,并且抑制作用随着蛋白终浓度的增大以及作用时间的延长而增强。不同类别的蛋白抑制作用没有明显差别。结论:结核分枝杆菌的部分分泌蛋白能够抑制肝癌细胞HepG-2的生长。     

结核分枝杆菌融合蛋白Ag85B-Hsp16．3、Ag85B-ESAT6和分泌蛋白Hspl6．3体外对人肝癌细胞HepG-2的作用

目的：探讨结核分枝杆菌融合蛋白Ag85B-Hspl6．3、Ag85B-ESAT6及分泌蛋白Hspl6-3对人肝癌细胞HepG-2的作用。方法：将已构建的含3种目的基因的表达载体pProEXHTa-Ag85B-Hspl6．3、pProEXHTa-Ag85B-ESAT6和pProEXHTb-Hspl6．3,分别转入宿主菌EcoliDH5α中,诱导表达后分别获得Ag85B-Hspl6．3、Ag85B-ESAT6和Hspl6．3三种蛋白,采用Ni^2＋亲和层析柱进行纯化,并用透析方法进行目的蛋白的复性。复性的蛋白按照不同浓度和作用时间分别与肝癌细胞HepG-2反应,用MTT法检测细胞生长情况。结果：三种蛋白被成功纯化并复性。MTT数据统计分析显示,终浓度101xg／ml的三种蛋白对HepG-2细胞生长没有明显作用,当三种蛋白的终浓度分别为20、40、801μg／ml时均能够抑制HepG-2细胞的生长,并且抑制作用随着蛋白终浓度的增大以及作用时间的延长而增强。不同类别的蛋白抑制作用没有明显差别。结论：结核分枝杆菌的部分分泌蛋白能够抑制肝癌细胞HepG-2的生长。     

香菇Latcripin-8蛋白诱导HepG-2细胞凋亡的 机制研究

目的探讨香菇Latcripin-8蛋白对HepG-2肝癌细胞凋亡的诱导作用及其机制。方法运用倒置显微镜、透射电镜、吉姆萨染色法和流式细胞仪法对细胞凋亡进行检测。采用Western blot法检测JAK3、STAT3和P53等凋亡相关蛋白的表达水平。采用Caspase-8活性检测盒检测Caspase-8活性。结果 HepG-2细胞经Latcripin-8蛋白作用后,倒置显微镜、透射电镜和吉姆萨染色等检测显示在形态学上Latcripin-8蛋白结构域抑制HepG-2细胞生长,并伴有凋亡小体产生。流式细胞仪检测显示该蛋白诱导HepG-2细胞凋亡。Western blot法检测结果显示JAK3和STAT3等蛋白的表达水平随药物浓度的增加而下降,而P53随药物浓度增加其表达量上升;凋亡相关因子Caspase-8的活性与对照组相比也均有不同程度的提高。结论香菇Latcripin-8蛋白结构域可能是通过JAK-STAT信号通路来诱导HepG-2肝癌细胞凋亡。     

牛磺酸对化疗荷瘤小鼠增效减毒作用的研究

目的:探讨牛磺酸对化疗荷瘤小鼠的增效减毒作用.方法:采用小鼠H22移植瘤动物模型,观察不同荆量牛磺酸(taurine,Tau)与环磷酰胺(cyclophosphamide,CTX)联合用药的抗肿瘤作用;检测外周血白细胞数,骨髓有核细胞数;测定脾指数,胸腺指数;采用MTT法检测NK细胞活性和脾淋巴细胞转化率.结果:Tau增强CTX的抗肿瘤作用;拮抗CTX对白细胞和骨髓有核细胞的抑制;提高免疫器官指数,促进淋巴细胞增殖,增强NK细胞活性.结论:Tau对荷瘤小鼠化疗具有增效减毒作用.     

桦木酮酸对肿瘤细胞SGC-7901、HepG-2及S180荷瘤小鼠肿瘤细胞的影响

为研究桦木酮酸体外对SGC-7901、HepG-2及体内对S180荷瘤小鼠的影响,采用MTT与肿瘤细胞集落形成能力实验观察桦木酮酸对HepG-2和SGC-7901作用。通过抑瘤率观察其对S180荷瘤小鼠的影响;HE染色观察其对S180肿瘤细胞形态学的影响。结果显示：桦木酮酸可抑HepG-2和SGC-7901细胞的生长,MTT与肿瘤集落形成能力实验测得其IC50分别为68．14和110．77μmol／L。连续给药8d后,150和75ms／kg／d剂量的桦木酮酸对S180的抑制率分别为68．3％和41．5％（P〈0．05）;HE染色发现肿瘤细胞表现较为明显的胀亡现象：细胞淡染、细胞体积增大,细胞核结构相对完整。提示桦木酮酸体内、外对肿瘤细胞均有一定的抑制作用,其作用可能与其引起肿瘤细胞胀亡有关。     

膜型Tim-3分子促进荷瘤小鼠抗肿瘤免疫应答的研究

目的 研究膜型Tim-3分子对H22肝癌细胞生长的抑制效应,探讨膜型Tim-3分子对荷瘤小鼠免疫系统的影响.方法 以H22肝癌细胞接种于BALB/c小鼠大腿肌肉建立小鼠实体瘤模型,采用原位注射裸DNA的方法在小鼠体内表达膜型Tim-3进行基因治疗,观察Tim-3对肿瘤生长的抑制作用;采用RTPCR技术在肿瘤生长不同时期检测Tim-3对4-1BB、IFN-γ、galectin-9等免疫相关基因表达的影响;流式细胞术检测膜型Tim-3对脾细胞增殖活性及细胞毒活性的影响;观察Tim-3 ＋4-1 BBL协同抗肿瘤作用.结果 体内转染表达Tim-3对肿瘤的生长有明显的抑制作用.流式细胞术结果显示,在小鼠荷瘤早期,Tim-3可提高脾细胞在特异性抗原刺激下的增殖反应和对H22肿瘤细胞的细胞毒作用;Tim-3与4-1BBL协同作用时抗肿瘤作用更加明显.结论 膜型Tim-3可在免疫启动阶段作为正向免疫调节因子增强抗肿瘤免疫应答,并可与4-1 BBL协同产生更强的抑瘤效应.     

荔枝核离子交换树脂分离物对肝癌细胞体外增殖及凋亡的影响

为探讨荔枝核提取物对人肝癌细胞HepG-2增殖的影响,采用MTT法检测样品对HepG-2细胞的增殖抑制活性,选取活性最好的组分进行Hoechest 33258染色,检测其对HepG-2细胞的致凋亡能力;细胞凋亡率及细胞周期的改变采用PI染色和流式细胞术进行测定。结果表明,荔枝核提取物及纯化后的多个组分都显示出对HepG-2细胞的增殖抑制活性,其中组分L2．3效果最好,对HepG-2细胞有明显的剂量依赖性增殖抑制作用（P〈0．05）;倒置显微镜下可见经也．3处理72h后细胞形态明显变小变圆,正常存活的细胞随药物浓度增加而减少;Hoechest 33258染色后处理组HepG-2细胞染色质固缩,出现呈致密浓染蓝白色颗粒状荧光的凋亡小体;在100、50μg／mL浓度时,L2．3处理48h后HepG-2细胞凋亡率显著增高（P〈0．05）,G0／G1期细胞减少（P〈0．05）,S期细胞增多（P〈0．01）,G2／M期细胞减少。以上结果证明荔枝核提取物可通过诱导细胞凋亡,影响细胞周期分布抑制HepG-2细胞增殖。     

褐藻多糖硫酸酯免疫调节和抗肿瘤活性研究

目的研究褐藻多糖硫酸酯(Fucoidan)体外抗肿瘤及免疫调节作用。方法采用MTT法检测Fu-coidan对Hca-F肝癌细胞体外生长和对正常小鼠脾淋巴细胞增殖的影响;中性红比色法检测Fucoidan对小鼠脾Mφ吞噬活性的影响;ELISA法检测Fucoidan对脾细胞细胞因子分泌水平的影响。结果浓度低于1 000μg/ml时Fu-coidan对Hca-F肝癌细胞体外生长抑制作用不明显(P0.05);Fucoidan对脾淋巴细胞增殖、Mφ吞噬活性及细胞因子IL-6、IL-10、IL-12、IL-18和TNF-α的分泌均有增加趋势。结论 Fucoidan对体外培养的小鼠Hca-F肝癌细胞生长有一定的抑制作用;可提高细胞与分子免疫应答水平,调节细胞因子分泌,发挥抗肿瘤作用。     

新合成的7-氮杂异靛蓝的体内外抗肿瘤作用

对新合成的7-氮杂靛玉红类衍生物N1-(正–丁基)-7-氮杂异靛蓝[N1-(n-butyl)-7-azaisoindigo,7-AI-b]的体内外抗肿瘤作用的研究,为研发具有自主知识产权的靛玉红类抗肿瘤新药打下基础。以不同浓度的7-AI-b作用于肿瘤细胞,MTT法检测细胞活性;建立Heps肝癌荷瘤小鼠模型,评价7-AI-b的体内抗肿瘤作用;计算肝脏指数(liver index,LI)、胸腺指数(thymusindex,TI)、脾脏指数(spleen index,SI),评价化合物的毒副作用;紫外法检测小鼠血清丙二醛(malondialdehyde,MDA)、谷胱甘肽(glutathione,GSH)的含量;HE染色观察肿瘤组织的变化;试剂盒检测细胞周期激酶(cyclin-dependent kinases,CDKs)的活性。结果发现,7-AI-b抑制肿瘤细胞增殖的IC50值为28~40μmol/L,并以时间和剂量依赖性方式抑制A549细胞的增殖。7-AI-b对Heps肝癌具有抑制作用且抑瘤率达到61.85%,与5-Fu的相近;而7-AI-b对于小鼠的毒副作用明显小于后者,表现为体重正常增长,TI、SI和LI均无明显降低;等剂量的7-AI-b效果也明显优于靛玉红;并且7-AI-b能增强荷瘤小鼠的抗氧化能力,使得MDA水平降低,GSH水平升高。另外,7-AI-b对于正常肝细胞株WRL-68和肝癌细胞HepG-2的毒性作用有明显差别,即具有一定的肿瘤细胞选择性。然而,7-AI-b对CDK2/cyclinA的抑制作用较弱。由此,7-AI-b可有效地抑制肿瘤的生长,且毒副作用较小,其机制可能与抑制细胞周期激酶CDKs有关,所以7-AI-b可以作为新型抗肿瘤药物进行研究。     

黄芩提取物抗氧化性及其对肝癌HepG-2细胞的抑制作用

本研究探讨黄芩提取物的抗氧化能力以及对肝癌细胞HepG-2生长的影响。通过分光光度法、邻苯三酚自氧化法测定不同黄芩提取物对DPPH自由基、超氧阴离子的清除效果,以此考察其抗氧化性能;同时采用MTT法测定不同黄芩提取物对HepG-2细胞的生长影响来研究其抗肿瘤作用。结果显示,3种不同的黄芩提取物均具有较好的抗氧化性能,并对肝癌细胞的生长具有明显的抑制作用,黄芩正丁醇部分、黄芩乙酸乙酯部分及黄芩石油醚部分对肝癌细胞作用72h后,对HepG-2细胞的最大抑制率分别达到57.2%、51.8%和35.2%。3种黄芩提取物具有较强的抗氧化活性,且对肝癌细胞的生长有一定的抑制作用。     

The Use of Human,Bovine, and Camel Milk Albumins in Anticancer Complexes with Oleic Acid

Oleic acid (OA) is a monounsaturated fatty acid that upon binding to milk proteins, such as α-lactalbumin and lactoferrin, forms potent complexes, which exert selective anti-tumor activity against malignant cells but are nontoxic for healthy normal cells. We showed that the interaction of OA with albumins isolated from human, bovine, and camel milk results in the formation of complexes with high antitumor activity against Caco-2, HepG-2, PC-3, and MCF-7 tumor cells. The antitumor effect of the complexes is mostly due to the action of oleic acid, similar to the case of OA complexes with other proteins. Viability of tumor cells is inhibited by the albumin-OA complexes in a dose dependent manner, as evaluated by the MTT assay. Strong induction of apoptosis in tumor cells after their treatment with the complexes was monitored by flow cytometry, cell cycle analysis, nuclear staining, and DNA fragmentation methods. The complex of camel albumin with OA displayed the most pronounced anti-tumor effects in comparison with the complexes of OA with human and bovine albumins. Therefore, these results suggest that albumins have the potential to be used as efficient and low cost means of tumor treatment.     

小鼠ALB启动子/增强子驱动HSV-tk 对肝脏细胞的杀伤效应

利用小鼠白蛋白(ALB)启动子／增强子及单纯疱疹病毒胸苷嘧啶激酶(HSV-tk)DNA构建了载体pLLTK,以研究该载体对肝脏细胞的特异性杀伤效应。首先,为了比较载体的肝脏细胞特异转录活性,以绿色荧光蛋白(GFP)基因为报告基因构建了载体pLE(仅含小鼠ALB启动子)、pLLE(含小鼠ALB启动子和上游增强子)和pLEL(含小鼠ALB启动子和下游增强子),分别转染到人肝细胞株Hep—G2与小鼠乳腺上皮细胞株HC-11,荧光显微镜与流式细胞术分析GFP的表达。然后将载体pLLTK转染到Hep-G2研究对细胞的杀伤效应。结果发现：小鼠ALB启动子／增强子能驱动GFP肝脏特异表达;HSV-tk在Hep-G2表达使细胞具有更昔洛韦(GCV)敏感性,在GCV作用7d后,MTT分析细胞的生存率,pLLTK转染细胞表现明显的细胞死亡(53％),而阴性对照组pcDNA3．1转染细胞没有明显变化(仅2％细胞死亡)。以上结果表明所有的载体具有肝脏细胞特异性,为利用该载体产生肝脏损伤的转基因小鼠提供了细胞水平的实验依据。     

Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis

Magnolol, a hydroxylated biphenyl compound isolated from the Chinese herb Hou p'u of Magnolia officinalis, has been reported to have anti-cancer activity. In the present study, magnolol at very low concentrations of 3-10 microM inhibited DNA synthesis and decreased cell number in cultured human cancer cells (COLO-205 and Hep-G2) in a dose-dependent manner, but not in human untransformed cells such as keratinocytes, fibroblasts, and human umbilical vein endothelial cells (HUVEC). Magnolol was not cytotoxic at these concentrations and this indicates that it may have an inhibitory effect on cell proliferation in the subcultured cancer cell lines. [(3)H] thymidine incorporation and flow cytometry analyses revealed that magnolol treatment decreased DNA synthesis and arrested the cells at the G0/G1 phase of the cell cycle. Moreover, the magnolol-induced cell cycle arrest occurred when the cyclin-CDK system was inhibited, just as p21 protein expression was augmented. When magnolol concentration was increased to 100 microM, apoptosis was observed in COLO-205 and Hep-G2 cells, but not in cultured human fibroblasts and HUVEC. COLO-205 cells implanted subcutaneously in nude mice formed solid tumors; subsequent daily i.p.-injections of magnolol led to profound regression of these tumors of up to 85%. In these tumors, an increase in the expression of p21 protein level and the occurrence of apoptosis were observed. These findings demonstrate for the first time that magnolol can inhibit the proliferation of tumor cells in vitro and in vivo.     

Chlorogenic acid inhibits proliferation in human hepatoma cells by suppressing noncanonical NF-κB signaling pathway and triggering mitochondrial apoptosis

Chlorogenic acid (CGA), a phenylpropanoid derived from Eucommia ulmoides Oliver, has been shown to exhibit potent cytotoxic and anti-proliferative activities against several human cancers. However, the effects of CGA on hepatocellular carcinoma (HCC) and the underlying mechanisms have not been intensively studied. In this study, the CGA treatment effects on the viability of human hepatoma cells were investigated by MTT assay. Our data showed that CGA could dose-dependently inhibit the activity of human hepatoma cells Hep-G2 and Huh-7, but did not affect the activity and growth of normal human hepatocyte QSG-7701. The genes and pathways influenced by CGA treatment were explored by RNA sequencing and bioinformatics analysis, which identified 323 differentially expressed genes (DEGs) involved in multiple pharmacological signaling pathways such as MAPK, NF-κB, apoptosis and TGF-β signaling pathways. Further analyses by real-time quantitative PCR, Western blot and flow cytometry revealed that CGA effectually suppressed the noncanonical NF-κB signaling pathway, meanwhile it activated the mitochondrial apoptosis of HCC by upregulation of the BH3-only protein Bcl-2 binding component 3 (BBC3). Our findings demonstrated the potential of CGA in suppressing human hepatoma cells and provided a new insight into the anti-cancer mechanism of CGA.

     

Biochemical characterization,cytotoxic, antimutagenic,anticancer and molecular docking studies on Tecomella undulata

In this study bioassay-guided screening of Tecomella undulate was performed for its cytotoxic, antimutagenic and anticancer potential. The ariel parts were extracted on a polarity basis (methanol, dichloromethane and hexane). The in vivo toxicity was assessed on Caenorhabditis elegans, and its locomotion was affected by Tecomella undulata hexane (TUAH) the most. Ames test for antimutagenicity showed Tecomella undulata methanol (TUAM) exhibited against mutagen 2AA showed inhibition of 71.03% and 26.32% 2AA in TA98 while in in vitro MTT assay on carcinoma cell lines TUAM showed 68.1% cytotoxicity. Moreover, In resazurin assay on fibroblast cells African green monkey kidney VERO and on the panel of carcinoma cell lines, the most effective extract was TUAM on liver HepG-2 with CC₅₀ value 117.37 ± 4.73 µg/ml followed by on lungs A549 with 142.01 ± 5.3. Furthermore, for the bioassay-guided screening, the selectivity index was calculated for TUAM CC₅₀ ratio on HepG-2 and VERO which showed a decent 2.77 score. After column chromatography, the fraction TU-63 should remarkable cytotoxic effect in dose–response manner assay as (Hep-G2) CC₅₀ value 11. 67 ± 1.37 µg/ml followed by (A549) CC₅₀ value 17.23 ± 0.58 µg/ml. For qualitative analysis of anticancer potential LC-ESI-MS/MS the potential phytochemicals were identified. In silico molecular modelling against selected carcinogenic proteins. The results suggest Tecomella undulate the substantial anticancer potential which supports potential natural anticancer therapeutic drug candidate development for combating cancer.